The Healey-Driscoll administration and the Massachusetts Life Sciences Center (MLSC) have announced $21.4 million in tax incentive awards to 19 life sciences companies. The awards, provided through the MLSC’s Tax Incentive Program, are expected to create 1,155 new life sciences industry jobs in Massachusetts. The MLSC Tax Incentive program is offered to companies engaged in life […]

The FDA has approved Cobenify, an oral medication for the treatment of schizophrenia in adults. Cobenify represents the first new class of schizophrenia medicine in several decades and introduces a fundamentally new approach to treating the illness. “Today’s landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where after more […]

Boston-based Bicara Therapeutics, a clinical-stage biopharma developing therapies for patients with solid tumors, this week announced the closing of its initial public offering which raised gross proceeds of approximately $362 million. Bicara’s lead asset, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody […]

Moderna used its annual R&D Day to announce program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline including data readouts in the company’s respiratory vaccine portfolio and a revised financial framework. Over the past three years, Moderna’s robust pipeline has achieved milestones across multiple late-stage clinical trials, and its early-stage portfolio […]

Massachusetts added almost 3,000 net new jobs in the biopharma industry in 2023, accounting for nearly 17% of overall job growth in the state. Meanwhile, the research and development workforce grew by 3.7%, even as the national R&D workforce decreased by 0.5%. This is according to the annual MassBio Industry Snapshot which tracks the state’s life […]

Commenting on Biogen’s second quarter, President and CEO Christopher Viehbacher said: “Biogen delivered strong financial performance…thanks to solid execution against our business strategy, which is aimed at transforming the Company to deliver sustainable growth. We saw continued positive momentum across new product launches and are pleased with the trends we see with key products going […]

Eli Lilly has opened its Lilly Seaport Innovation Center (LSC), a research and development facility in the Seaport dedicated to advancing Lilly’s efforts in RNA and DNA-based therapies as well as discovering new drug targets across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration and chronic pain. “The opening of LSC expands upon Lilly’s […]

Moderna is receiving $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS). The project award will support late-stage development for an […]

The FDA has approved Kisunla, Eli Lilly’s Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD), which includes people with mild cognitive impairment as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.  Once-monthly Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when […]

AbbVie has announced the acquisition of privately held Cambridge biotech Celsius Therapeutics. Celsius is pioneering new therapies for patients with inflammatory disease. Celsius’ lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of inflammatory bowel disease (IBD). TREM1 has been identified as a key […]